| Computer Motion, Inc. | |||
| Ticker: | RBOT | 130-B Cremona Drive | |
| Exchange: | NASDAQ-National Market | Goleta, CA 93117 | |
| Industry: | Manufacturing (SIC Code 3845) | (805) 968-9600 | |
| Type of Shares: | Common Shares | Filing Date: | 6/18/97 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 8/11/97 | |
| Non-U.S. Shares: | 0 | Filing Range: | $13.00 - $15.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $14.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.98 | |
| Offering Amount: | $35,000,000 | Selling: | $0.55 | |
| Expenses: | $600,000 | Reallowance: | $0.10 | |
| Shares Out After: | 7,118,468 |
| Manager | Tier | Phone |
| Montgomery Securities | Lead Manager | (415) 627-2100 |
| Piper Jaffray Incorporated | Co-manager | (612) 342-6220 |
| Issuer's Law Firm: | Stradling, Yocca, Carlson & Rauth |
| Bank's Law Firm: | Wilson, Sonsini, Goodrich & Rosati |
| Auditor: | Arthur Andersen |
| Registrar/Transfer Agent: | U. S. Stock Transfer Corporation |
Dollar amounts in U.S. millions except for per share data | |||||
| 3 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/96 | 3/31/97 | 3/31/96 | 3/31/97 | ||
| Revenue: | $4.06 | $1.37 | $0.68 | Assets: | $6.67 |
| Net Income: | -$4.56 | -$1.50 | -$0.89 | Curr Assets: | |
| EPS: | -$0.88 | -$0.28 | -$0.18 | Liabilities: | $7.72 |
| Prior EPS: | -$0.71 | -$1.39 | -$0.56 | Curr Liabilities: | |
| Cash Flow/Oper: | -$3.49 | Equity: | -$1.05 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company develops and markets proprietary robotic and computerized surgical systems that enhance a surgeon's performance and centralize and simplify a surgeon's control of the operating room. The company believes that its products and technologies under development have the potential to revolutionize surgery and the OR by providing a surgeon with the precision and dexterity necessary to perform complex, minimally invasive surgical procedures including fully endoscopic multivessel coronary artery bypass grafts and by enabling a surgeon to control critical devices in the OR through simple verbal commands. The company believes that its products and technologies under development will broaden the scope and increase the effectiveness of minimally invasive surgery, improve patient outcomes, and create a safer, more efficient and cost effective OR. The company's current commercial product, AESOP, is an FDA-cleared, robotic endoscope positioning system. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for repayment of debt, research and development, sales and marketing and working capital. |